期刊
CANCER LETTERS
卷 348, 期 1-2, 页码 20-28出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.02.010
关键词
Pancreatic cancer; Obatoclax; Olaparib; Drug combination
类别
资金
- Start-up Fund from Jilin University, Changchun, China
- National Natural Science Foundation of China (NSFC) [31271477, 81200363]
In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. While both agents were able to cause growth arrest and limited apoptosis, the combination of the two was able to synergistically cause growth arrest and non-apoptotic cell death. Furthermore, in an in vivo xenograft model, the combination caused substantially increased tumor necrosis compared to either treatment alone. Our results support further investigation of the combination of Bcl-2 and PARP inhibitors for the treatment of pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据